Cadence OTC Promotes Confidence This Valentine’s Day
Cadence Partners with Antiviral Discovery Consortium to Spearhead Rapid Development of Treatments for Viral Pandemics
SAN JOSE, Calif. & SANTA FE, N.M.--(BUSINESS WIRE)--Cadence Design Systems, Inc. (Nasdaq: CDNS) announced today that it has completed the acquisition of OpenEye Scientific Software, Inc. (“OpenEye”). The addition of OpenEye’s technologies and experienced team accelerates the Cadence® Intelligent System Design™ strategy by extending Cadence’s computational software core competency to molecular modeling and simulation that is targeted to life sciences.
SAN JOSE, Calif. & SANTA FE, N.M.--(BUSINESS WIRE)--Cadence Design Systems, Inc. (Nasdaq: CDNS) announced today that it has entered into a definitive agreement to acquire privately held OpenEye Scientific Software, Inc., a leading provider of computational molecular modeling and simulation software being widely and increasingly used by pharmaceutical and biotechnology companies for drug discovery.
Telehealth firm Cadence nets $41M to bring hospital care home
Mallinckrodt is trying to reduce its reliance on cash cow product Acthar (corticotropin) for infantile spasms and multiple sclerosis, which brought in sales of almost $309m in the third quarter of 2017, down 6%. Acthar’s slowdown has been attributed by the company to payer resistance affecting prescription fulfilment, and the drug has also been in the spotlight in the US over price increases that culminated in a payer lawsuit a few weeks ago.
Exela Pharma Sciences LLC v. Lee
Mallinckrodt Buys Ikaria for $2.3 Billion for Neonatal Care